“…Hence, although the overall trend is for lower GABA+ in ASD, it seems that results are inconsistent, owing perhaps to differences in experimental procedures and analysis methods, regions of interest (ROIs), and sample characteristics, as summarized in several recent reviews [Ajram et al, 2019;Ford & Crewther, 2016;Schür et al, 2016]. In the case of Glx, results are even less conclusive, with studies reporting reduced [Bernardi et al, 2011;Corrigan et al, 2013;DeVito et al, 2007;Hegarty et al, 2018;Horder et al, 2013Horder et al, , 2018Kubas et al, 2012;Tebartz Van Elst et al, 2014], equivalent [Ajram et al, 2017;Aoki et al, 2012;Brix et al, 2015;Carvalho Pereira et al, 2018;Endres et al, 2017;Friedman et al, 2006;Goji et al, 2017;Hardan et al, 2008;Horder et al, 2018;Ito et al, 2017;Libero et al, 2016;Mikkelsen et al, 2017;Robertson et al, 2016], or increased [Bejjani et al, 2012;Brown, Singel, Hepburn, & Rojas, 2013;Doyle-Thomas et al, 2014;Page et al, 2006] levels in ASD. In the current study, we sought to extend previous results by measuring GABA+ and Glx simultaneously using current methodology, in a relatively large sample of well-characterized individuals with ASD, including previously unexamined ROIs, and testing the functional relevance of neurometabolite levels by correlating individual differences in MRS measures with behavior and ASD symptomatology.…”